Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satralizumab in NMOSD
NCT05269667Phase 4Terminated
- Sponsor
- Roche
- Start
- Aug 2022
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 4 trial of satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Roche. Started Aug 2022; status: terminated.
02
Drugs
satralizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT05269667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05269667.